Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DE2Z7V
|
|||
| Drug Name |
BT1718
|
|||
| Drug Type |
Bicycle toxin conjugate
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2a | [1] | |
| Company |
Bicycle Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-14 (MMP-14) | Target Info | Inhibitor | [2] |
| KEGG Pathway | TNF signaling pathway | |||
| GnRH signaling pathway | ||||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Signaling events mediated by focal adhesion kinase | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Senescence and Autophagy in Cancer | |||
| Activation of Matrix Metalloproteinases | ||||
| Degradation of collagen | ||||
| AGE/RAGE pathway | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. | |||
| REF 2 | ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.